IL33 and familial pancreatic carcinoma: Synergistically, biochemical factors like ROS can stimulate and amplify IL-33 secretion in collaboration with the mycobiome.149 This IL-33 secretion may participate in triggering a type 2 immune response, hastening the pancreatic cancer progression along with reducing survival.152